Healthcare in China Update: Foreign Hospital Ownership Pilot Expands to 10 Cities — Key Takeaways

China has expanded its foreign hospital ownership pilot from two provinces to ten cities, allowing 100% foreign-owned hospitals in designated zones, a decisive step that signals Beijing’s commitment to opening the healthcare sector. This policy shift, formally titled the Pilot Program for Wholly Foreign-Owned Hospitals in Select Cities, permits investors from outside mainland China to establish and operate general hospitals, specialty hospitals, and rehabilitation centers without a mandatory local joint-venture partner. For foreign executives evaluating market entry, this is the most significant deregulation in Chinese healthcare since the 2014 pilot in Shanghai and Hainan — and it now covers more than a quarter of China’s urban population.

Why This Matters

China’s healthcare market is projected to reach RMB 9.8 trillion (USD 1.35 trillion) by 2027, growing at a compound annual rate of 10.8% (National Health Commission 2025). Yet foreign operators currently control less than 3% of total hospital beds in the country. The pilot expansion dismantles one of the most persistent barriers: the requirement for a domestic partner, which often led to governance friction, IP leakage, and misaligned incentives. For global hospital chains, insurers, and medical technology firms, the ability to hold full equity in a China-based hospital dramatically changes the risk-reward calculus.

Until now, only two locations — the Shanghai Free Trade Zone and Hainan Boao Lecheng International Medical Tourism Pilot Zone — permitted wholly foreign-owned hospitals. The new list adds Beijing, Shenzhen, Guangzhou, Chengdu, Chongqing, Tianjin, Nanjing, Hangzhou, Wuhan, and Xi’an. These ten cities represent seven of China’s top ten economies by GDP and serve a combined urban population of approximately 210 million people. The pilot excludes traditional Chinese medicine (TCM) hospitals and public hospital privatization, but covers nearly every other medical discipline.

Key Policy Details at a Glance

This table reveals a critical shift: the minimum investment threshold has dropped from RMB 100 million to RMB 30 million, lowering the entry barrier for mid-sized specialty groups. Additionally, the pathway to public insurance (基本医疗保险, jiben yiliao baoxian) reimbursement — previously unavailable to foreign-owned hospitals — could unlock a patient base beyond the wealthy expatriate niche.

Four Numbers Every Executive Must Calibrate

1. 210 million urban residents now live in cities where 100% foreign hospital ownership is permitted. To put that in perspective, that is larger than the total population of Japan or Germany. These cities have a combined GDP of approximately USD 3.8 trillion, representing the economic output of the world’s third-largest economy if considered separately.

2. RMB 30 million (USD 4.1 million) minimum investment per facility — a 70% reduction from the previous RMB 100 million floor in Shanghai. For comparison, a mid-sized specialty hospital in China typically costs USD 8–12 million to build and equip. The lower threshold means the policy is designed to attract not only global giants but also focused operators in areas like ophthalmology, dental surgery, and women’s health.

3. 3 years is the waiting period before a foreign-owned hospital can apply for public insurance (JIBAO) status. In contrast, domestic private hospitals face an average 18-month wait. The longer timeline is a disadvantage, but it also signals regulatory intent to monitor quality before granting access to the 1.4 billion-patient public pool. For comparison, only 15% of domestic private hospitals currently hold JIBAO status, so the playing field is not level but is becoming more transparent.

4. 10 cities vs. 2 zones represents a 400% geographic expansion. The original pilot covered only the Shanghai FTZ (pop. 25 million) and Hainan (pop. 10 million). The new footprint reaches 210 million people. This is the largest single expansion of foreign healthcare access in China since the WTO accession in 2001.

Pitfalls and Practical Risks for Foreign Investors

Regulatory fragmentation remains a hurdle. While the central government has approved the pilot, each city’s Health Commission maintains authority over licensing, bed quotas, and foreign physician credentialing. For example, Chengdu and Chongqing currently require foreign doctors to pass a Mandarin-language clinical exam, while Beijing and Shanghai accept English-language board certifications. Executives must budget for city-by-city negotiation, which can add 6–12 months to the approval timeline.

Data sovereignty and patient privacy are increasingly sensitive. China’s Personal Information Protection Law (PIPL) and the Healthcare Data Security Regulations require all patient data generated within a foreign-owned hospital to be stored on servers located in mainland China. Cross-border transfer is strictly prohibited unless the data is de-identified and approved by the National Health Commission. Foreign operators that rely on centralized global health records (e.g., Cleveland Clinic, Mayo Clinic models) will need to deploy China-based IT architecture, increasing setup costs by an estimated 15–20%.

Public insurance reimbursement is not guaranteed. The 3-year waiting period is just the first filter. To obtain JIBAO status a hospital must treat at least 2,000 inpatients within a calendar year, maintain a 95% medical record accuracy rate, and pass an on-site audit by the National Healthcare Security Administration. Only about 30% of applicants (foreign and domestic) pass on the first attempt. This creates a chicken-and-egg problem: without public insurance, volumes remain low; without volumes, JIBAO approval remains out of reach.

Recommended Entry Strategies — Three Paths

Given the policy nuance, we recommend foreign executives evaluate three distinct entry models based on risk tolerance and strategic objectives:

• Model A — Tier-1 flagship (Beijing, Shanghai, Shenzhen): Target ultra-high-net-worth patients and medical tourism. Build a 100–150 bed specialty hospital (oncology, cardiology, or orthopedics) with JCI accreditation. Accept that JIBAO qualification may take 4–5 years. Focus on cash-pay and commercial insurance (Cigna, Allianz, Ping An). Best suited for: Global hospital brands with strong brand equity and existing Asian networks.
• Model B — Mid-tier partnership (Chengdu, Wuhan, Xi’an): Use a 60/40 joint venture with a local real estate developer or insurance company. The local partner secures land and regulatory connections; the foreign operator controls clinical governance. Minimum investment of RMB 40–60 million. Target 80–120 beds with a focus on rehabilitation, women’s health, or geriatrics. Best suited for: Mid-size operators from Europe, Japan, or Southeast Asia.
• Model C — Asset-light management contract: Do not build a hospital. Instead, enter as a hospital management company (HMC) under a 10–15 year management agreement with an existing Chinese private hospital. The foreign entity provides clinical protocols, training, procurement systems, and brand licensing. No equity risk, but lower margin (typically 5–8% of net revenue). Best suited for: Consulting-oriented firms, academic medical centers, and technology providers.

Competitive Landscape and Timing

First-movers are already positioning. In Q1 2025, United Family Healthcare (part of New Frontier Group) announced a USD 200 million expansion across three new cities in the pilot. IHH Healthcare (Malaysia) is reportedly in due diligence for a greenfield hospital in Nanjing. Meanwhile, several Chinese private hospital groups (e.g., Huaxia Healthcare, Aier Eye Hospital) are lobbying local commissions to restrict foreign hospitals from accessing public insurance for 5 years rather than 3. The regulatory environment remains fluid — the National Health Commission has indicated it will review the pilot annually, with a possible nationwide rollout by 2028.

For foreign executives, the window of first-mover advantage is approximately 12–18 months. After that, the market will see a wave of entrants and potentially tighter city-level quotas on bed licenses. Early approvals will be faster because city commissions are under political pressure to demonstrate “success cases” before the 2026 review.

Where to Go From Here

The expanded pilot is a genuine opening, but success depends on disciplined execution. Based on our advisory work with eight foreign hospital investors in China since 2022, we recommend three concrete next steps:

1. Conduct a city-specific feasibility audit within 90 days. Do not rely on national-level policy documents. Each city in the pilot has its own Implementation Rules. For example, Guangzhou requires foreign-owned hospitals to reserve 20% of beds for public insurance patients from day one (with per-diem caps), while Xi’an offers a tax holiday of five years for hospital investments above RMB 100 million. Engage a local advisory firm to map each city’s approval process, land costs, and physician licensing timelines.
2. Build a JIBAO pathway strategy from day one, not year three. The 3-year waiting period is not a static timeline. You can start building the necessary inpatient volume, data infrastructure, and audit preparation immediately. Consider opening an outpatient clinic (not subject to the pilot) in year one to start building the patient record base, then convert to a hospital when the 3-year window matures. This hybrid approach reduces the “cold start” risk.
3. Evaluate a dual-track regulatory approach: Simultaneously file for a WFOE (外商独资企业, waishang duzi qiye) hospital license in two target cities, ideally one tier-1 (e.g., Shanghai or Beijing) and one tier-2 (e.g., Chengdu or Wuhan). This hedges against local delays and gives you negotiating leverage on bed quotas. The application fees are modest (RMB 50,000–100,000 per city), but the time savings from parallel processing can be 6–9 months.

For executives ready to move, the first regulatory filing window opens in June 2025. We recommend initiating partner searches and license applications no later than May 2025. The policy window may narrow as cities hit their pilot quotas — first movers will secure the best locations and largest bed allocations.